{"id":"NCT00425373","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension","officialTitle":"A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive Patients","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-11","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2007-01-23","resultsPosted":"2011-02-04","lastUpdate":"2011-04-29"},"enrollment":1474,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Essential Hypertension"],"interventions":[{"type":"DRUG","name":"Valsartan + amlodipine 40/2.5 mg","otherNames":[]},{"type":"DRUG","name":"Valsartan + amlodipine 40/5 mg","otherNames":[]},{"type":"DRUG","name":"Valsartan + amlodipine 80/2.5 mg","otherNames":[]},{"type":"DRUG","name":"Valsartan + amlodipine 80/5 mg","otherNames":[]},{"type":"DRUG","name":"Valsartan 40 mg","otherNames":[]},{"type":"DRUG","name":"Valsartan 80 mg","otherNames":[]},{"type":"DRUG","name":"Amlodipine 2.5 mg","otherNames":[]},{"type":"DRUG","name":"Amlodipine 5 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Valsartan + amlodipine 40/2.5 mg","type":"EXPERIMENTAL"},{"label":"Valsartan + amlodipine 40/5 mg","type":"EXPERIMENTAL"},{"label":"Valsartan + amlodipine 80/2.5 mg","type":"EXPERIMENTAL"},{"label":"Valsartan + amlodipine 80/5 mg","type":"EXPERIMENTAL"},{"label":"Valsartan 40 mg","type":"ACTIVE_COMPARATOR"},{"label":"Valsartan 80 mg","type":"ACTIVE_COMPARATOR"},{"label":"Amlodipine 2.5 mg","type":"ACTIVE_COMPARATOR"},{"label":"Amlodipine 5 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure. The study will investigate the dose response relationship for the combinations, monotherapies, and placebo.","primaryOutcome":{"measure":"Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)","timeFrame":"Baseline to end of study (Week 8)","effectByArm":[{"arm":"Valsartan + Amlodipine 40/2.5 mg","deltaMin":-13.5,"sd":0.62},{"arm":"Valsartan + Amlodipine 40/5 mg","deltaMin":-16.5,"sd":0.6},{"arm":"Valsartan + Amlodipine 80/2.5 mg","deltaMin":-12.6,"sd":0.62},{"arm":"Valsartan + Amlodipine 80/5 mg","deltaMin":-17,"sd":0.61},{"arm":"Valsartan 40 mg","deltaMin":-8.5,"sd":0.6},{"arm":"Valsartan 80 mg","deltaMin":-8.8,"sd":0.61},{"arm":"Amlodipine 2.5 mg","deltaMin":-10.3,"sd":0.61},{"arm":"Amlodipine 5 mg","deltaMin":-13.4,"sd":0.61},{"arm":"Placebo","deltaMin":-4.8,"sd":0.61}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":20},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":166},"commonTop":["Nasopharyngitis"]}}